Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply
Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.
You may also be interested in...
Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.
After a few false starts, it seems that the EU regulator has begun preparing the ground for a review of Russia’s adenovirus-based COVID-19 vaccine.
A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.